Access Bio, Inc. (KOSDAQ:950130)

Market Cap	124.87B -30.4%
Revenue (ttm)	31.26B -72.2%
Net Income	-82.12B
EPS	-2,332.00
Shares Out	35.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	657,100
Average Volume	1,219,241
Open	3,485.00
Previous Close	3,550.00
Day's Range	3,380.00 - 3,575.00
52-Week Range	2,625.00 - 7,360.00
Beta	n/a
RSI	50.29
Earnings Date	May 27, 2026

About Access Bio

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solu...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2002
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950130

Financial Performance

In 2025, Access Bio's revenue was 31.26 billion, a decrease of -72.21% compared to the previous year's 112.46 billion. Losses were -82.12 billion, 23525.9% more than in 2024.